跳至主要内容
临床试验/ACTRN12624000873527
ACTRN12624000873527尚未招募Unknown

The CASSOWARY (CAncer genomic riSk ScOres in primARY Care) Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice

niversity of Melbourne0 个研究点目标入组 392 人开始时间: 2024年7月17日最近更新:
适应症

试验速览

阶段
Unknown
状态
尚未招募
发起方
入组人数
392

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Diagnosis
盲法
Open (masking not used)

入排标准

年龄范围
40 Years 至 59 Years(—)
性别
All

入选标准

  • Are aged between 40 and 59 years
  • Are able to read and write English and competent to give informed consent
  • Are contactable over the next 12 months for trial follow-up

排除标准

  • Have been diagnosed with any of breast, prostate, colorectal cancer or melanoma;
  • Have any alarm symptoms that are potentially indicative of any cancer:
  • Once or more and not investigated:
  • Blood in stool or urine
  • For more than four weeks and not investigated:
  • Problems with urination
  • Unexplained weight loss
  • An unusual pain, lump or swelling anywhere in the body
  • A new or changed spot on the skin;
  • Have a known genetic predisposition to any of the four cancers in question or, a first-/second-degree relative with a genetic predisposition and the participants has not had genetic testing themselves. This includes (but is not limited to) by a pathogenic variant in any of the following genes:
  • CRC: Lynch syndrome (MLH1, PMS2, MSH2, MSH6, EPCAM), familial adenomatous polyposis (APC);
  • BrCa: BRCA1, BRCA2, PALB2, ATM, CHEK2;
  • PrCa: BRCA1, BRCA2, HOXB13;
  • Melanoma: CDKN2A/p16.
  • Have any health condition or illness that, in the opinion of the participant or researcher, would impact their appropriateness for cancer screening or their ability to participate

研究者

发起方
niversity of Melbourne

相似试验